122
Views
1
CrossRef citations to date
0
Altmetric
Biomedical Science in Brief

TIMP1 and TIMP3 circulating levels and promoter polymorphisms in breast cancer

, , & ORCID Icon
Pages 236-238 | Received 25 Feb 2021, Accepted 06 Apr 2021, Published online: 30 Apr 2021

References

  • Fahad Ullah M. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol. 2019;1152:51–64.
  • Bahreini F, Ramezani S, Shahangian SS, et al. miR-559 polymorphism rs58450758 is linked to breast cancer. Br J Biomed Sci. 2020;77:29–34.
  • Mashayekhi F, Saberi A, Mashayekhi S. Serum TIMP1 and TIMP2 concentration in patients with different grades of meningioma. Clin Neurol Neurosurg. 2018;170:84–87.
  • Balkhi S, Mashayekhi F, Salehzadeh A, et al. Matrix metalloproteinase (MMP)-1 and MMP-3 gene variations affect MMP-1 and −3 serum concentration and associates with breast cancer. Mol Biol Rep. 2020;47:9637–9644.
  • Vizoso FJ, González LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007;96:903–911.
  • Olivares‐Urbano MA, Griñán‐Lisón C, Zurita M, et al. Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: a pilot study. J Cell Mol Med. 2020;24:139–148.
  • Jackson HW, Defamie V, Waterhouse P, et al. TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. 2017;17:38–53.
  • Su CW, Huang YW, Chen MK, et al. Polymorphisms and plasma levels of tissue inhibitor of metalloproteinase-3: impact on genetic susceptibility and clinical outcome of oral cancer. Medicine. 2015;94:e2092.
  • Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol. 2011;12:233.
  • Gu P, Xing X, Tänzer M, et al. Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia. 2008;10:563–572.
  • Peterson NB, Beeghly-Fadiel A, Gao Y-T, et al. Polymorphisms in tissue inhibitors of metalloproteinases-2 and -3 and breast cancer susceptibility and survival. Int J Cancer. 2009 15;125:844–850.
  • Chang WS, Liu LC, Hsiao CL, et al. The contributions of the tissue inhibitor of metalloproteinase-1 genotypes to triple negative breast cancer risk. Biomedicine. 2016;6:4.
  • Wu ZS, Wu Q, Yang JH, et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008;122:2050–2056.
  • Tsai HP, Chen SC, Chien HT, et al. Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer. World J Surg Oncol. 2012;10:42.
  • Wieczorek E, Galicki M, Tomasik B, et al. Expression of MMP and TIMP mRNA in peripheral blood leukocytes of patients with invasive ductal carcinoma of the breast. Int J Biol Markers. 2016;31:e309–16.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.